QTRX · Quanterix Corp
Market Cap
$121.07M
Shares
47.29M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.56
Open$2.52
Day$2.50–2.59
52W close$2.42–8.06
Avg vol 30d742K
Short int4.8M · 10.2% float · 8.3d
Short vol57%
Last earningsAug 10, 2026
DataJan 2020–Sep 2026
Filing10-Q · Aug 10
Up next
Next earnings call
Nov 14, 2026
Est · unconfirmed
· in 9 wks
filed Aug 10, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$153.41M
Trailing 12 months
Net income (TTM)
−$123.11M
Trailing 12 months
Revenue growth YoY
+34.4%
Year over year
Operating margin
-99.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.3%
Year over year · more shares
Price change (1Y)
-46.6%
Trailing year
Short interest
10.2%
Latest settlement · 8.3 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.8 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−44%
below
Price vs 50-day avg
−23%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−10%
trailing
6-month return
−40%
trailing
YTD return
−60%
this year
Relative strength
−58%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +37 funds added
Insider flow
Accumulating
Net +$286.4K over 90 days · 0% sells
Short interest
Rising
10.19% of float · ▲ +1.8% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
Gross margin
173%
contracting
EPS growth
−151%
Y/Y
Free cash flow
$-79.8M
Balance sheet
$173.9M
net cash
Quant / Vol
risk profile
Volatility
90%
annualized · 1-yr
Max drawdown
−70%
past year
ATR
8.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 10, 2026
Revenues
· 2026
$142M – $148M
prior FY $138.9M
midpoint +4.4% Y/Y
Non-GAAP gross margins
· 2026
Non-GAAP
48% – 50%
2026 year-end cash balance
· 2026
$80M
Prior guidance
period ended
· from the 8-K filed Aug 8, 2024
2024 revenue guidance
· 2024 Full Year
$134M – $138M
Guided vs delivered
· last 1 settled
2024 revenue guidance
2024 Full Year
guided $134M – $138M
$137.42M
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−44%
Bearish
Price vs 50-day avg
−23%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $5 — 200d above 50d
Institutional flow
Accumulating
+4% holders QoQ · +37 funds added
Insider flow
Accumulating
Net +$286.4K over 90 days · 0% sells
Short interest
Rising
10.19% of float · ▲ +1.8% MoM · 8.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
133 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $2
Now $3 · 2%
Range high $8
vs 200-day avg -44%
vs 50-day avg -23%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QTRX
this stock
Quanterix Corp
|
$121.07M | -59.7% | +64.5% | — | 10.2% |
|
ABT
Abbott Laboratories
|
$177.58B | -18.6% | +5.7% | 28.6 | 1.3% |
|
MDT
Medtronic plc
|
$116.35B | -5.3% | +8.4% | 22.4 | 0.9% |
|
SYK
Stryker Corp
|
$105.70B | -21.6% | +11.2% | 28.6 | 2.0% |
|
BSX
Boston Scientific Corp
|
$62.29B | -54.9% | +12.5% | 17.4 | 3.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QTRX | -0.8% | -10.5% | -40.2% | -4.1% | -59.8% |
| SPY | -1.2% | -1.8% | +17.8% | -0.4% | +12.1% |
| vs SPY | +0.4% | -8.7% | -58.0% | -3.8% | -71.8% |
Key facts
CIK
1503274
CUSIP
74766Q101
13F (30d)
46 filings
46 filers
Visit website
Investor relations